Abstract Title:

The Effect of Krill Oil and n-3 Polyunsaturated Fatty Acids on Human Osteosarcoma Cell Proliferation and Migration.

Abstract Source:

Curr Drug Targets. 2015 Jan 7. Epub 2015 Jan 7. PMID: 25563592

Abstract Author(s):

S U Xiao, Philline Tanalgo, Marcel Bustos, Crispin R Dass

Article Affiliation:

S U Xiao

Abstract:

Osteosarcoma (OS) is a neoplastic condition afflicting mostly the young, as the lesion usually occurs in areas of bone growth with tumour cells metastasising to the lungs in advanced disease. There is no real cure for the disease, with conventional drugs causing side-effects that decrease the quality of life of sufferers. Newer and safer drugs are needed, and one avenue is to use natural compounds that can stunt the growth of the tumour. In this study, two such biological entities were evaluated: krill oil and fish oil. Human OS cells were exposed to krill oil, fish oil, EPA and DHA in time-course assays lasting up to 72h. Krill oil inhibited 23, 50 and 64% of cell proliferation at 24, 48 and 72h respectively, while fish oil resulted in no significant changes although an increase was observed at 24h. Interestingly EPA and DHA promoted OS cell proliferation and migration in this neoplasia. The inhibitory effect of krill oil was comparable to 0.5 and 1µM doxorubicin, a commonly used clinical drug for OS treatment. These results indicate that krill oil may be used in combination with standard clinical practices to control primary tumour growth, and more importantly, metastasis.

Study Type : In Vitro Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.